|Senior Pharmaceutical & Technologies Executive and Present SVP, Chief Information and facts Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon’s Advisory Board
Vancouver, BC – March three, 2021 – Entheon Biomedical Corp. (CSE: “ENBI” OTC: “ENTBF” FSE: “1XU1”) (“Entheon” or the “Firm”), a biotechnology corporation focused on creating psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Unique Advisor of Information Science and Regulatory Affairs, delivering knowledge on the improvement of the Company’s information technique style study style and advise on regulatory relationships and information technique.
Ms. Maher has served as an executive and consultant for key pharmaceutical and information and facts technologies businesses, such as IBM, Gilead, Schering-Plough, Merck, Allergan, and Teva Pharmaceuticals. Ms. Maher is at the moment SVP, Chief Information and facts Officer, North America of Kyowa Kirin International plc., and joins Entheon as its Unique Advisor of Information Science and Regulatory Affairs.
Ms. Maher will be consulting on the improvement and implementation of Entheon’s information management systems for the collection, organization and evaluation of information from upcoming pre-clinical and clinical trials, partnership initiatives, private clinic partnerships, and numerous technological initiatives. In addition, Ms. Maher will inform the Firm of most effective practices for the style and implementation of safety measures as they relate to the company’s information plan, whilst also informing regulatory technique and connection as it relates to advancing conversations and applications with Overall health Canada, the FDA and EMA regulatory authorities.
“We would like to extend a warm welcome to Ms. Nancy Maher, who brings a wealth of practical experience and business expertise to Entheon. Ms. Maher understands the value of information with regard to future solution improvement and in characterizing the one of a kind variables of diagnosis and drug response in patient populations, and we are thrilled to have access to her one of a kind knowledge,” mentioned Chief Executive Officer Timothy Ko.